COMBACTE-CDI’s primary goal is to develop a detailed understanding of the epidemiology and clinical impact of Clostridium difficile infection across Europe. The ultimate goal is to contribute to improved prevention and treatment options for such infections that are responsible for extensive morbidity, mortality and health care costs.
The 3-year COMBACTE-CDI project merges European expertise on clinical, diagnostic and therapeutic issues related to C. difficile infection (CDI). It brings together experts that previously have partnered in large international CDI projects, such as EUCLID, LUCID, ORCHID and ECDIS-NET, and combines all that knowledge with CLIN-Net and LAB-Net, the largest IMI-funded existing clinical and laboratory networks in Europe for carrying out challenging epidemiological and interventional studies. Add to the sum EPI-Net, a network mapping all European surveillance activities related to antimicrobial resistance. The combination of all these parties has invigorating potential. It is an ideal platform to extend our knowledge of this key infection, and ultimately to help with the development of better management modalities.
A collaborative approach comprising three scientific work packages (WPs):
- A large epidemiology study will be undertaken across Europe in WP1 to quantify the burden of CDI (incidence, distribution, recurrence, morbidity, mortality, transmission) across the whole healthcare economy;
- A case/control study in WP2, which along with data collected in a questionnaire will enable the consortium to assess current practices in Europe (guidelines, testing, surveillance, treatment, cost) and their potential impacts;
- WP3 will create a rich, European, research platform that will provide support for future proof-of-concept and clinical studies of new prevention and treatment strategies for CDI.
The three interrelated research WPs will be supported by a management work package (WP4).
Clostridium difficile infection (CDI)
CDI is one of the most prevalent healthcare associated infections, affecting both hospitalized patients and individuals in the community; notably, there is an increasing realization that cases also occur in subjects not recently exposed to healthcare interventions, including antibiotics. CDI poses an extensive burden of morbidity, mortality and healthcare resource utilization, and so requires effective prevention and management strategies. Epidemiological data are, however, limited and studies typically have examined only part of a healthcare economy and usually have been focused on single countries/healthcare systems. Thus, there is a lack of robust, comprehensive data on the impact of CDI across countries in Europe. Furthermore, we know that large variations in the frequency of testing and the sensitivity of CDI diagnostics across European countries mean that the size of the problem is underestimated.
Management Board Members COMBACTE-CDI
From left to right: Prof. Dr. Marc Bonten (UMC Utrecht), Dr. Andrew Nyborg (Medimmune), Prof. Dr. Mark Wilcox (University of Leeds), Dr. Charles Knirsch (Pfizer)